Court Sets BIOLASE Board at Four Members

Court Sets BIOLASE Board at Four Members 
IRVINE, CA -- (Marketwired) -- 03/21/14 --  BIOLASE, Inc. (NASDAQ:
BIOL) announced that on March 20, 2014, the Chancery Court of
Delaware entered a status quo order establishing a Board of Directors
consisting of Federico Pignatelli, Chief Executive Officer and
Chairman, Frederic H. Moll, Norman J. Nemoy and James R. Talevich
(the "Board") pending outcome of the litigation filed by Oracle on
March 11, 2014. During the status quo period, any Board decision
requires approval of at least three of four of these directors and,
in certain cases, 10 day notice prior to the decision. 
Oracle Partners, L.P. which, with Larry Feinberg, report beneficial
ownership of 16% of the Company's common stock, had sought a
temporary restraining order from the Chancery Court requiring
approval by a Board composed of six individuals, including three of
its nominees. On March 11, 2014, Oracle filed a lawsuit in the
Chancery Court of Delaware seeking this temporary order followed by a
Court determination of the composition of the Board.  
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment, CAD/CAM intraoral scanners, and in-office
milling machines and 3D printers; products that are focused on
technologies that advance the practice of dentistry and medicine. The
Company's proprietary laser products incorporate approximately 300
patented and patent-pending technologies designed to provide
biologically clinically superior performance with less pain and
faster recovery times. Its innovative products provide cutting-edge
technology at competitive prices to deliver the best results for
dentists and patients. BIOLASE's principal products are revolutionary
dental laser systems that perform a broad range of dental procedures,
including cosmetic and complex surgical applications, and a full line
of dental imaging equipment. BIOLASE has sold more than 25,000
lasers. Other laser products under development address ophthalmology
and other medical and consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at, Facebook at, Twitter at,
Pinterest at, LinkedIn at, Google+ at, Instagram at and YouTube at 
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
Forward Looking Information 
This press release may contain forward-looking statements and
information within the meaning of safe harbor provided by the
Securities Reform Act of 1995 that are based on the current
expectations and estimates by BIOLASE. These forward-looking
statements can be identified through the use of words such as
"anticipates," "expects," "intends," "plans," "believes," "seeks,"
"estimates," "may," "will," and variations of these words or similar
expressions. Forward-looking statements are based on BIOLASE's
current, preliminary expectations and are subject to risks,
uncertainties and other factors which may cause the Company's actual
results to differ materially from the statements contained herein,
and are described in the Company's reports it files with the
Securities and Exchange Commission, including its annual and
quarterly reports. No undue reliance should be placed on
forward-looking statements. Such information is subject to change,
and BIOLASE undertakes no obligation to update such statements. 
For further information, please contact:  
Joele Frank
Wilkinson Brimmer Katcher
Eric Brielmann / Annabelle Rinehart
Press spacebar to pause and continue. Press esc to stop.